resTORbio is a biopharmaceutical company developing therapeutics for treating age-related diseases that is headquartered in Boston, Massachusetts and was founded in 2016 by Chen Schor and Joan Mannick.
On January 1, 2017 resTORbio completed their series A funding round with $25 million in funding from PureTech Health.
On November 30, 2017 resTORbio completed their series B funding rounds with $40 million in funding from OrbiMed (lead investor), Rock Springs Capital, Recharge Capital, Quan Capital, Nest.Bio Ventures, and Fidelity Management and Research Company.
Timeline
Funding Rounds
Patents
Further Resources
resTORbio launches Phase Ib/IIa trial of RTB101 to treat Parkinson's
Drugdevelopment-technology
Web
References
Organization
CompanyCompany attributes
Biotechnology
Biopharmaceutical
Immunotherapy
Drug development
Therapeutics
Therapy
Boston
Massachusetts
Rock Springs Capital
OrbiMed
Recharge Capital
Quan Capital
Nest.Bio Ventures
Fidelity Investments
ReCyte Therapeutics
Series B roundOther attributes
Adicet Bio
United StatesCategories
Related Topics
Contributors
- 1
Dawson Sewell
Writing about startups. - 2
Elena Ruban
Freelancer now. Graduated from Financial University - 3
Keeri Tramm
Accomplished manager, brand communicator, and burgeoning data analyst. - 4
Lax Mariappan
Technopreneur, Open source enthusiast, author, speaker. Co-founder of Eternus Global. Crafting applications for the medical industry. - 5
Neelam Jhaveri
Techno Geek + Gamer + Fashionista + Sense of Humor = It's ME - 6
Rebecca Hammond
MA English I HDip Psychology - Following AI, behavioural and educational psychology - 7
Jude Gomila
Founder and CEO of Golden, Entrepreneur. Investor in 200+ companies. Cantabrigian (Gonville and Caius). Interested in the Universe. - 8
Duzenko Andrey
Extensive experience in development and interaction with the community - 9
Katrina-Kay Pettitt
Data Duchess @ Golden - 10
Bhupendra Solanki
Researcher
